← Eichor
Condition: Namd Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Namd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Shanghai Refreshgene Technology Co., Ltd. · NCT06141460A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Phase 2 · 1 location(s) · Innovent Biologics Technology Limited (Shanghai R&D Center) · NCT07275840Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Phase 4 · 1 location(s) · Medical University of Vienna · NCT05093374A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participant
Phase 3 · 36 location(s) · Amgen · NCT07614776Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Phase 1 · 2 location(s) · Benobio Co., Ltd. · NCT05803785Gene Therapy(FT-003) for Wet AMD
Phase 1/Phase 2 · 1 location(s) · Frontera Therapeutics · NCT06492863Regulatory Post-Marketing Surveillance Study for Brolucizumab
Phase N/A · 28 location(s) · Novartis Pharmaceuticals · NCT04985487Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Relat
Phase 3 · 8 location(s) · Ocular Therapeutix, Inc. · NCT07516132Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Phase 3 · 31 location(s) · Innostellar Biotherapeutics Co.,Ltd · NCT07317934Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth
NA · 1 location(s) · Singapore National Eye Centre · NCT07249216Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg
Phase 3 · 79 location(s) · Adverum Biotechnologies, Inc. · NCT07482176CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigat
EARLY_Phase 1 · 2 location(s) · HuidaGene Therapeutics Co., Ltd. · NCT06031727A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Tre
Phase 4 · 52 location(s) · Genentech, Inc. · NCT04853251Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Phase 1/Phase 2 · 1 location(s) · Sinocelltech Ltd. · NCT06672536Real-world Study of Aflibercept 8 mg in nAMD
Phase N/A · 27 location(s) · Peking University People's Hospital · NCT07640997Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
EARLY_Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07053358Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul
Phase 3 · 94 location(s) · 4D Molecular Therapeutics · NCT07064759A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degenera
Phase 1 · 3 location(s) · Youxin Chen · NCT06213038Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degen
Phase 2 · 4 location(s) · Adverum Biotechnologies, Inc. · NCT07630649A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese
Phase 3 · 16 location(s) · Hoffmann-La Roche · NCT05562947Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual A
Phase 3 · 129 location(s) · AbbVie · NCT07007065Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Chengdu Origen Biotechnology Co., Ltd. · NCT06458595Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Phase 2 · 5 location(s) · EyebioKorea, Inc. · NCT06487039Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Chengdu Origen Biotechnology Co., Ltd. · NCT05672121A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Intra-IMMUSG Pte Ltd · NCT07547228Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degener
Phase N/A · 1 location(s) · University of Udine · NCT06899360Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 9 location(s) · Skyline Therapeutics (US) Inc. · NCT05986864A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Phase N/A · 10 location(s) · Skyline Therapeutics · NCT06346600A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Phase 3 · 59 location(s) · Hoffmann-La Roche · NCT06847542
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.